Currently, there are no effective treatments for cocaine overdose and it is responsible for more serious intoxications and deaths than any other illicit drug. Previous attempts to develop pharmacotherapies to treat cocaine overdose have been met by one unsuccessful attempt after another. Finally, we have identified a group of drugs that can prevent cocaine-induced behavioral toxicity, under rigorous in vivo conditions, such as would exist in an emergency room. All of our compounds were designed to target sigma receptors, a known binding site for cocaine. Our preliminary studies in mice reveal that over a dozen of our compounds prevent cocaine-induced convulsions and lethality, with up to 100 percent of treated mice surviving a normally fatal overdose. Our best compound even prevents death when administered after an overdose. To our knowledge, no other drug has been reported to be as safe and effective against the toxic effects of cocaine. Initial studies also show that our novel compounds dramatically attenuate the locomotor stimulatory effects of cocaine, indicating that they have the ability to mitigate the actions of cocaine across a range of functional systems. Our preliminary studies provide compelling evidence for the potential therapeutic significance of our novel compounds, and suggest that sigma receptors represent viable, but relatively unrecognized, substrates for the development of anti-cocaine agents. Therefore, the studies in this proposal utilize a multidisciplinary approach to: 1) identify the sigma receptor subtypes that mediate the anti-cocaine actions, 2) evaluate the specificity of the anti-cocaine agents for sigma receptors, 3) identify the areas of the brain that are involved, and 4) determine whether sigma receptors influence the local anesthetic effects of cocaine. Together, we anticipate that these studies will lead to the development of new and effective agents for the treatment of cocaine overdose and addiction.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
1R01DA011979-01A2
Application #
6131790
Study Section
Human Development Research Subcommittee (NIDA)
Program Officer
Appel, Nathan M
Project Start
2000-09-30
Project End
2003-04-30
Budget Start
2000-09-30
Budget End
2001-04-30
Support Year
1
Fiscal Year
2000
Total Cost
$181,875
Indirect Cost
Name
University of Oklahoma Health Sciences Center
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
937727907
City
Oklahoma City
State
OK
Country
United States
Zip Code
73117
Nguyen, Linda; Kaushal, Nidhi; Robson, Matthew J et al. (2014) Sigma receptors as potential therapeutic targets for neuroprotection. Eur J Pharmacol 743:42-7
Matsumoto, Rae R; Nguyen, Linda; Kaushal, Nidhi et al. (2014) Sigma (?) receptors as potential therapeutic targets to mitigate psychostimulant effects. Adv Pharmacol 69:323-86
Motel, William C; Healy, Jason R; Viard, Eddy et al. (2013) Chlorophenylpiperazine analogues as high affinity dopamine transporter ligands. Bioorg Med Chem Lett 23:6920-6922
Xu, Yan-Tong; Robson, Matthew J; Szeszel-Fedorowicz, Wioletta et al. (2012) CM156, a sigma receptor ligand, reverses cocaine-induced place conditioning and transcriptional responses in the brain. Pharmacol Biochem Behav 101:174-80
Kaushal, Nidhi; Robson, Matthew J; Vinnakota, Harsha et al. (2011) Synthesis and pharmacological evaluation of 6-acetyl-3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-one (SN79), a cocaine antagonist, in rodents. AAPS J 13:336-46
Matsumoto, Rae R; Li, Su-Min; Katz, Jonathan L et al. (2011) Effects of the selective sigma receptor ligand, 1-(2-phenethyl)piperidine oxalate (AC927), on the behavioral and toxic effects of cocaine. Drug Alcohol Depend 118:40-7
Xu, Yan-Tong; Kaushal, Nidhi; Shaikh, Jamaluddin et al. (2010) A novel substituted piperazine, CM156, attenuates the stimulant and toxic effects of cocaine in mice. J Pharmacol Exp Ther 333:491-500
Fishback, James A; Robson, Matthew J; Xu, Yan-Tong et al. (2010) Sigma receptors: potential targets for a new class of antidepressant drug. Pharmacol Ther 127:271-82
Matsumoto, Rae R (2009) Targeting sigma receptors: novel medication development for drug abuse and addiction. Expert Rev Clin Pharmacol 2:351-8
Matsumoto, Rae R; Shaikh, Jamaluddin; Wilson, Lisa L et al. (2008) Attenuation of methamphetamine-induced effects through the antagonism of sigma (sigma) receptors: Evidence from in vivo and in vitro studies. Eur Neuropsychopharmacol 18:871-81

Showing the most recent 10 out of 28 publications